secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001404644-24-000059
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene's NGN-401 Rett syndrome gene therapy selected for FDA START Pilot Program
--------------------------------------------------------------------------------

- NGN-401 one of only three CBER programs chosen for FDA's START Pilot Program.
- START provides enhanced communications with FDA to accelerate development of rare disease therapies.
- Phase 1/2 trial of NGN-401 ongoing; favorable safety data from first three patients reported.
- Interim efficacy data from the trial expected in Q4 2024.
- Company aims to advance NGN-401 toward potential registrational study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000059/0001404644-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000059/ngne-20240603.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer